{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T22:36:27Z","timestamp":1792708587896,"version":"4.5.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T00:00:00Z","timestamp":1738540800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim International GmbH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jaad.2025.01.089","type":"journal-article","created":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T00:55:14Z","timestamp":1741308914000},"page":"1235-1242","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Effect of spesolimab on sustained disease control in patients with generalized pustular psoriasis: Post hoc analysis of the EFFISAYIL 2 study"],"prefix":"10.1016","volume":"92","author":[{"given":"Kenneth B.","family":"Gordon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Augustin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Barker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yayoi","family":"Tada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark G.","family":"Lebwohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Hofmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Thoma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice B.","family":"Gottlieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2025.01.089_bib1","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s40257-021-00658-9","article-title":"Treatment options and goals for patients with generalized pustular psoriasis","volume":"23","author":"Krueger","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaad.2025.01.089_bib2","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1080\/1744666X.2022.2116003","article-title":"Generalized pustular psoriasis is a disease distinct from psoriasis vulgaris: evidence and expert opinion","volume":"18","author":"Bachelez","year":"2022","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.jaad.2025.01.089_bib3","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s13555-024-01103-5","article-title":"Clinical and disease burden of patients with generalized pustular psoriasis: a review of real-world evidence","volume":"14","author":"Bhutani","year":"2024","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.jaad.2025.01.089_bib4","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/jdv.18851","article-title":"Generalized pustular psoriasis: a global Delphi consensus on clinical course, diagnosis, treatment goals and disease management","volume":"37","author":"Puig","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2025.01.089_bib5","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s40257-021-00663-y","article-title":"Impact of generalized pustular psoriasis from the perspective of people living with the condition: results of an online survey","volume":"23","author":"Reisner","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaad.2025.01.089_bib6","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s13555-021-00493-0","article-title":"Unmet medical needs in the treatment and management of generalized pustular psoriasis flares: evidence from a survey of Corrona Registry Dermatologists","volume":"11","author":"Strober","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.jaad.2025.01.089_bib7","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1111\/1346-8138.17449","article-title":"Spesolimab, the first-in-class anti-IL-36R antibody: from bench to clinic","volume":"51","author":"Morita","year":"2024","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaad.2025.01.089_bib8","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1007\/s40265-022-01801-4","article-title":"Spesolimab: first approval","volume":"82","author":"Blair","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.jaad.2025.01.089_bib9","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(23)01378-8","article-title":"Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomized, placebo-controlled trial","volume":"402","author":"Morita","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2025.01.089_bib10","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI)\u2013a simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2025.01.089_bib11","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s13555-022-00835-6","article-title":"Design of Effisayil 2: a randomized, double-blind, placebo-controlled study of spesolimab in preventing flares in patients with generalized pustular psoriasis","volume":"13","author":"Morita","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.jaad.2025.01.089_bib12","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s40257-021-00653-0","article-title":"Clinical disease measures in generalized pustular psoriasis","volume":"23","author":"Burden","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaad.2025.01.089_bib13","article-title":"The role of IL-36 in the pathophysiological processes of autoimmune diseases","volume":"12","author":"Chen","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jaad.2025.01.089_bib14","doi-asserted-by":"crossref","DOI":"10.1111\/exd.14934","article-title":"Cutaneous findings and treatments in deficiency of interleukin-36 receptor antagonist (DITRA): a review of the literature","volume":"33","author":"Okorie","year":"2024","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jaad.2025.01.089_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1292941","article-title":"The role of the interleukin-36 axis in generalized pustular psoriasis: a review of the mechanism of action of spesolimab","volume":"14","author":"Hawkes","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaad.2025.01.089_bib16","doi-asserted-by":"crossref","first-page":"6215","DOI":"10.1007\/s00018-021-03909-4","article-title":"IL-36 cytokines in inflammatory and malignant diseases: not the new kid on the block anymore","volume":"78","author":"Byrne","year":"2021","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.jaad.2025.01.089_bib17","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1007\/s00424-013-1284-2","article-title":"New insights into the mechanisms of itch: are pain and itch controlled by distinct mechanisms?","volume":"465","author":"Liu","year":"2013","journal-title":"Pflugers Arch"},{"key":"10.1016\/j.jaad.2025.01.089_bib18","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.3389\/fimmu.2019.02532","article-title":"Biology of IL-36 signaling and its role in systemic inflammatory diseases","volume":"10","author":"Yuan","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaad.2025.01.089_bib19","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1056\/NEJMoa2111563","article-title":"Trial of spesolimab for generalized pustular psoriasis","volume":"385","author":"Bachelez","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2025.01.089_bib20","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/jdv.18820","article-title":"Spesolimab improves patient-reported outcomes in patients with generalized pustular psoriasis: results from the Effisayil 1 study","volume":"37","author":"Navarini","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2025.01.089_bib21","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1111\/jdv.19830","article-title":"Psychometric validation of the psoriasis symptom scale, functional assessment of chronic illness therapy-fatigue and pain-visual analogue scale in patients with generalized pustular psoriasis","volume":"38","author":"Burden","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225001847?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225001847?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T17:03:12Z","timestamp":1777568592000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962225001847"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S0190962225001847"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2025.01.089","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of spesolimab on sustained disease control in patients with generalized pustular psoriasis: Post hoc analysis of the EFFISAYIL 2 study","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2025.01.089","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}